2.Tanner, CM, Aston, DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol. 2000;13:427–430.
3.Lang, AE, Lozano, AM. Parkinson's disease. First of two parts. N Engl J Med. 1998;339:1044–1053.
4.Guttman, M, Kish, SJ, Furukawa, Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ. 2003;168:293–301.
5.Braak, H, Del Tredici, K, Rub, U, de Vos, RA, Jansen Steur, EN, Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211.
6.Colcher, A, Simuni, T. Clinical manifestations of Parkinson's disease. Med Clin North Am. 1999;83:327–347.
7.Dhawan, V, Healy, DG, Pal, S, Chaudhuri, KR. Sleep-related problems of Parkinson's disease. Age Aging. 2006;35:220–228.
8.Koller, WC, Tse, W. Unmet medical needs in Parkinson's disease. Neurology. 2004;62(suppl 1):S1–S8.
9.Rascol, O, Goetz, C, Koller, W, Poewe, W, Sampaio, C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:1589–1598.
10.Hoehn, MM, Yahr, MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442.
11.Koller, W, Guarnieri, M, Hubble, J, Rabinowicz, AL, Silver, D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. 2005;112:221–230.
12.Cohen, G, Spina, MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989;26:689–690.
13.Schapira, AH, Obeso, J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559–562.
14.Aminoff, MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol. 2006;59:562–564.
15.Fahn, S, Oakes, D, Shoulson, I, et al.Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498–2508.
16.Thanvi, BR, Lo, TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80:452–458.
17.Adler, CH. Relevance of motor complications in Parkinson's disease. Neurology. 2002;58(suppl 1):S51–S56.
18.Muller, T, Russ, H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother. 2006;7:1715–1730.
19.Sato, K, Hatano, T, Yamashiro, K, et al.Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21:1384–1395.
20.Schrag, A, Quinn, N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000;123(pt 11):2297–2305.
21.Mazzella, L, Yahr, MD, Marinelli, L, Huang, N, Moshier, E, Di Rocco, A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy. Parkinsonism Relat Disord. 2005;11:151–155.
22.Mccoll, CD, Reardon, KA, Shiff, M, Kempster, PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord. 2002;17:1227–1234.
23.Rajput, AH, Fenton, ME, Birdi, S, et al.Clinical-pathological study of levodopa complications. Mov Disord. 2002;17:289–296.
24.Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson's deseaseclinical aspects. In: Marsden, CD, Fahn, S, eds. Movement Disorders. Boston, Mass: Butterworth Scientific; 1982;96–122.
25.Ahlskog, JE, Muenter, MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458.
26.Blanchet, PJ, Allard, P, Gregoire, L, Tardif, F, Bedard, PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189–193.
27.Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931–1938.
28.Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39:37–45.
29.Stacy, M, Bowron, A, Guttman, M, et al.Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726–733.
30.Nutt, JG, Woodward, WR, Carter, JH, Gancher, ST. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol. 1992;49:1123–1130.
31.Barbato, L, Stocchi, F, Monge, A, et al.The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol. 1997;20:394–401.
32.Nutt, JG, Carter, JH, Lea, ES, Sexton, GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002;51:686–693.
33.Obeso, JA, Rodriguez-Oroz, M, Marin, C, et al.The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62(suppl 1):S17–S30.
34.Metman, LV, Konitsiotis, S, Chase, TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000;15:3–8.
35.Olanow, CW, Obeso, JA, Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–687.
36.Chapuis, S, Ouchchane, L, Metz, O, Gerbaud, L, Durif, F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20:224–230.
37.Wilson, RE, Silver, D, Spears, JB, Van Lunen, BE. Implications of motor fluctuations in Parkinson's patients on chronic therapy (IMPACT) registry: quality of life (QOL) data. Mov Disord. 2006;21(suppl 1):S151.
38.Bloem, BR, Hausdorff, JM, Visser, JE, Giladi, N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord. 2004;19:871–884.
39.Martinez-Martin, P, Benito-Leon, J, Alonso, F, et al.Quality of life of caregivers in Parkinson's disease. Qual Life Res. 2005;14:463–472.
40.Witjas, T, Kaphan, E, Azulay, JP, et al.Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology. 2002;59:408–413.
41.van Laar, T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs. 2003;17:475–489.
42. Parcopa [package insert]. Milwaukee, Wis: Schwarz Pharma; 2006.
43. Sinemet [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
44. Sinemet CR [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
45. Stalevo [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2004.
46. Apokyn [package insert]. Research Triangle Park, NC: Mylan Bertek Pharmaceuticals, Inc.; 2004.
47. Parlodel Snap Tabs [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.
48. Permax [package insert]. Indianapolis, Ind: Eli Lilly & Co.; 2001.
49. Mirapex [package insert]. Ridgefield, Conn: Boehringer-Ingelheim International GmbH; 2006.
50. Requip [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
51. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2000.
52. Tasmar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.
53. Azilect [package insert]. Kansas City, Mo: Teva Pharmaceutical Industries, Ltd.; 2006.
54. Eldepryl [package insert]. Tampa, Fla: Somerset Pharmaceuticals; 1998.
55. Zelapar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.
56. Symadine [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.
57. Symmetrel [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; 2002.
58. Cogentin [package insert]. Whitehouse Station, NJ; Merck & Co., Inc.; 2006.
59. Artane [package insert]. Pearl River, NY: Lederle Pharmaceutical Division; 2003.
60.Grosset, KA, Bone, I, Grosset, DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20:1502–1507.
61.Koller, WC, Hutton, JT, Tolosa, E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53:1012–1019.
62.Olanow, CW, Watts, RL, Koller, WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1–S88.
63.Lieberman, A, Ranhosky, A, Korts, D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–168.
64.LeWitt, PA, Chang, F-L, Fazzini, E, Nausieda, PA, Daniel, T, Boroojerdi, B. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 17-20, 2005; Athens, Greece.
65.Poewe, W, Giladi, N, Maguire, D, Boroojerdi B. Rotigotine transdermal patch in patients with parkinson's disease and motor fluctuations. 24H symptom control in a placebo- and Pramipexole-controlled, randomized, double-blind, double dummy trial. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.
66.Pahwa, R, Factor, SA, Elmer, LW. Ropinirole 24-hour prolonged release reduces ‘off’ time in patients with parkinson's disease not optimally controlled with L-Dopa. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.
67.Dodd, ML, Klos, KJ, Bower, JH, Geda, YE, Josephs, KA, Ahlskog, JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377–1381.
68.Watts, RL, Jankovic, J, Waters, C, Rajput, A, Boroojerdi, B, Rao, J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–276.
69.Avorn, J, Schneeweiss, S, Sudarsky, LR, et al.Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62:1242–1248.
70.Pezzella, FR, Colosimo, C, Vanacore, N, et al.Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20:77–81.
71.Pontone, G, Williams, JR, Bassett, SS, Marsh, L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258–1261.
72.Sundberg, S, Scheinin, M, Illi, A, Akkila, J, Gordin, A, Keranen, T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol. 1993;36:451–456.
73.Zanettini, R, Antonini, A, Gatto, G, Gentile, R, Tesei, S, Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39–46.
74.Van Camp, G, Flamez, A, Cosyns, B, et al.Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179–1183.
75.Horvath, J, Fross, RD, Kleiner-Fisman, G, et al.Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656–662.
76.Waters, CH, Sethi, KD, Hauser, RA, Molho, E, Bertoni, JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426–432.
77.Stocchi, F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract. 2006;60:215–221.
78.Rascol, O, Brooks, DJ, Melamed, E, et al.Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947–954
79.Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241–248.
80.Goetz, CG, Poewe, W, Rascol, O, Sampaio, C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20:523–539.
81.Thomas, A, lacono, D, Luciano, AL, Armellino, K, Di Iorio, A, Onofrj, M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:141–143.
82.Luginger, E, Wenning, GK, Bosch, S, Poewe, W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15:873–878.
83.Weller, M, Kornhuber, J. Amantadine withdrawal and neuroleptic malignant syndrome. Neurology. 1993;43:2155.
84.Anticholinergic therapies in the treatment of Parkinson's disease. Mov Disord. 2002;17(suppl 4):S7–S12.
85.Katzenschlager, R, Sampaio, C, Costa, J, Lees, A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;CD003735.
86.Stocchi, F, Olanow, CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology. 2004;62(suppl 1):S56–S63.
87.Adler, CH, Singer, C, O'Brien, C, et al.Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55:1089–1095.
88.Borges, N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26:743–747.
89.Hauser, RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62(suppl 1):S64–S71.
90.Stocchi, F, Vacca, L, Grassini, P, et al.Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. Neurol Sci. 2003;24:217–218.
91.Parkinson Study Group. Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients. Ann Neurol. 1997;42:747–755.
92.Rinne, UK, Larsen, JP, Siden, A, Worm-Petersen, J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51:1309–1314.
93.Poewe, WH, Deuschl, G, Gordin, A, Kultalahti, E-R, Leinonen, M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–255.
94.Reichmann, H, Boas, J, Macmahon, D, Myllyla, V, Hakala, A, Reinikainen, K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111:21–28.
95.Brooks, DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(suppl 1):S39–S46.
96.Silver, DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother. 2004;4:589–599.
97.Brooks, DJ, Agid, Y, Eggert, K, Widner, H, Ostergaard, K, Holopainen, A; TC-INIT Study Group. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53:197–202.
98.Myllyla, V, Haapaniemi, T, Kaakkola, S, et al.Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand. 2006;114:181–186.
99.Dewey, RB Jr, Hutton, JT, LeWitt, PA, Factor, SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392.
100.Zijlmans, JC, Debilly, B, Rascol, O, Lees, AJ, Durif, F. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord. 2004;19:1006–1011.
101.Pahwa, R, Factor, SA, Lyons, KE, et al.Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–985.